Coherus BioSciences, Inc. Forecasted to Post FY2028 Earnings of $0.08 Per Share (NASDAQ:CHRS)

Coherus BioSciences, Inc. (NASDAQ:CHRS) – Equities researchers at HC Wainwright issued their FY2028 earnings estimates for Coherus BioSciences in a research note issued to investors on Monday, September 16th. HC Wainwright analyst D. Tsao expects that the biotechnology company will earn $0.08 per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Coherus BioSciences’ current full-year earnings is ($1.07) per share.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to the consensus estimate of $57.08 million.

Several other equities analysts have also commented on CHRS. UBS Group lowered Coherus BioSciences from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $4.00 to $1.50 in a research report on Friday, August 16th. StockNews.com cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Friday, September 6th. Finally, Robert W. Baird lowered their price objective on shares of Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Monday, July 1st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.92.

Coherus BioSciences Stock Up 1.0 %

CHRS opened at $1.05 on Thursday. The business’s fifty day simple moving average is $1.42 and its 200 day simple moving average is $1.81. Coherus BioSciences has a 52 week low of $1.01 and a 52 week high of $4.73. The stock has a market cap of $120.46 million, a PE ratio of -1.35 and a beta of 0.66.

Institutional Trading of Coherus BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its stake in Coherus BioSciences by 694.2% during the first quarter. BNP Paribas Financial Markets now owns 346,157 shares of the biotechnology company’s stock worth $827,000 after acquiring an additional 302,570 shares in the last quarter. Nomura Holdings Inc. lifted its holdings in shares of Coherus BioSciences by 225.1% during the fourth quarter. Nomura Holdings Inc. now owns 68,300 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 47,290 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Coherus BioSciences in the 1st quarter worth approximately $94,000. Birchview Capital LP purchased a new stake in shares of Coherus BioSciences in the 4th quarter worth approximately $366,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Coherus BioSciences during the 1st quarter valued at approximately $108,000. 72.82% of the stock is owned by hedge funds and other institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.